罗格列酮干预环孢素A所致肾脏急性损害的发生机制

Mechanism of rosiglitazone on prevention of acute cyclosporine nephropathy

目的探讨急性环孢素肾病（ACN）中肾脏乙酰肝素酶（HPA）的表达及罗格列酮（RGZ）对ACN的保护作用。方法低盐基础上建立ACN大鼠动物模型，在实验开始后的第14天处死大鼠，28只大鼠被随机分为对照组、单用罗格列酮组、模型组和治疗组。用免疫组化、逆转录聚合酶链反应观察HPA的表达量，用HE观察肾脏病理变化。结果与对照组[（325±5）g]及罗格列酮组[（353±8）g]相比，模型组[（261±6）g]体重显著下降（P〈0．05），治疗组[（286±10）g]下降缓慢（P〈0．05）。RGZ可降低ACN肾组织中HPA的表达量，改善ACN肾间质单个核细胞浸润。结论RGZ通过下调趋化因子HPA的表达，减轻ACN肾脏病理改变。

Objective To investigate the expression of heparanase（HPA） in the kidney of acute cyclosporine nephropathy（ ACN）, and the protective effect of rosiglitazone on rat kidney of ACN. Methods ACN rat model was established on the basis of low dose salt, and the rats were executed at 14th day. Twenty- eight rats were randomly assigned to control group, rosiglitazone group, model group and treatment group. Immunohistochemistry, RT - PCR were used to investigate the expression of HPA in kidney of ACN, and HE was used to observe renal pathological changes. Results The weights decreased significantly in model group [ （261 ± 6 ）g] （ P 〈 0. 05 ）, and decreased slowly in treatment group [ （286±10） g] （ P 〈 0. 05 ）, compared with control group [ （325 ± 5 ） g] and rosiglitazone group [ （353 ± 8）g]. Rosiglitazone may reduce the expression of HPA in kidney of ACN, and improved the in- filtration of mononuclear cell in renal interstitium of ACN. Conclusions Rosiglitazone may protect renal tissue of ACN by decreasing expression of HPA.